A

Abortions. See Spontaneous abortion

ACC. See US Army Chemical Corps

Acquired immune deficiency syndrome. See AIDS/HIV

ACS. See American Cancer Society

ACTH. See Adrenocorticotropic hormone

Acute lymphocytic leukemia (ALL). See Leukemia

Aacute Myelogenous Leukemia. See Veterans and Agent Orange: Herbicides/Dioxin Exposure and Acute Myelogenous Leukemia in the Children of Vietnam Veterans (Acute Myelogenous Leukemia)

Acute myelogenous leukemia (AML). See Leukemia

Acute myeloid leukemia (AML). See Leukemia

AD. See Alzheimer’s disease

ADA. See American Diabetes Association

Adipose tissue

TCDD distribution,

I: 130, 131, 168–169, 259, 269, 280;

IV: 42, 43, 64, 116, 117;

VI: 67–68

Adrenocorticotropic hormone (ACTH),

IV: 59

Aerial spraying,

I: 3, 24;

III: 135, 137, 139;

IV: 117, 120, 123, 150, 160, 303;

VI: 175–177, 185

military early research,

I: 25–26;

III: 28;

IV: 150

records of,

I: 84–85, 287

See also Herbicide application methods;

Herbicides

AFHS. See Air Force Health Study

Aflatoxin,

I: 453;

IV: 267

Africa, sub-Saharan,

II: 181;

III: 282;

IV: 267;

VI: 221

Age and aging

acute lymphocytic leukemia incidence, data for selected age groups,

III: 384;

IV: 9, 378

acute myeloid leukemia incidence, data for selected age groups,

III: 384;

IV: 378

amyotrophic lateral sclerosis,

V: 524

bone/joint cancer incidence, data for selected age groups,

III: 302;

IV: 288;

V: 279

brain cancer incidence, data for selected age groups,

III: 356;

IV: 351;

V: 339, 524

breast cancer incidence in US women, data for selected age groups,

III: 324;

IV: 314;

V: 301

cancer age-specific incidence,

I: 436–438

chronic lymphocytic leukemia incidence, data for selected age groups,

III: 384;

IV: 378

chronic myeloid leukemia incidence, data for selected age groups,

III: 384;

IV: 378

diabetes prevalence, data by age,

III: 492

epidemiologic studies, control of aging effects,

II: 261–262;

III: 409;

IV: 3, 13, 23

female reproductive system cancer incidence, data by type, for selected age groups,

III: 329, 330;

IV: 321;

V: 310

gastrointestinal tract cancer incidence, data by type for selected age groups,

III: 267;

IV: 250;

V: 244

Hodgkin’s disease incidence, data for selected age groups,

III: 372;

IV: 365;

V: 355

immune system,

IV: 31, 79

kidney cancer,

V: 334

laryngeal cancer incidence, data for selected age groups,

III: 292;

IV: 277;

V: 268

latency and,

II: 261–262, 273, 275;

III: 409, 414–415, 425, 428, 430;

IV: 254, 256, 264, 265

leukemia incidence, data by type, for selected age groups,

III: 384;

IV: 378;

V: 367

liver/intrahepatic bile duct cancers incidence, data for selected age groups,

III: 282;

IV: 267;

V: 260

lung cancer incidence, data for selected age groups,

III: 296;

IV: 281;

V: 272

melanoma incidence, data for selected age groups,

III: 313;

IV: 300;

V: 288

multiple myeloma incidence, data for selected age groups,

III: 377;

V: 361

nasal/nasopharyngeal cancer incidence, data for selected age groups,

III: 289;

IV: 273;

V: 265

non-Hodgkin’s lymphoma age of onset,

I: 436

non-Hodgkin’s lymphoma incidence, data for selected age groups,

III: 362;

IV: 356;

V: 344



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement